BRIOLI, ANNAMARIA
BRIOLI, ANNAMARIA
DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE (attivo dal 28/10/2011 al 31/12/2022)
Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma.
2013 Brioli A;Kaiser MF;Pawlyn C;Wu P;Gregory WM;Owen R;Ross FM;Jackson GH;Cavo M;Davies FE;Morgan GJ
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes
2014 Lucia Pantani;Elena Zamagni;Beatrice Anna Zannetti;Annalisa Pezzi;Paola Tacchetti;Annamaria Brioli;Katia Mancuso;Giulia Perrone;Serena Rocchi;Patrizia Tosi;Michele Cavo
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment
2015 Zannetti, Beatrice Anna; Zamagni, Elena; Santostefano, Marisa; De Sanctis, Lucia Barbara; Tacchetti, Paola; Mancini, Elena; Pantani, Lucia; Brioli, Annamaria; Rizzo, Raffaella; Mancuso, Katia; Rocchi, Serena; Pezzi, Annalisa; Borsi, Enrica; Terragna, Carolina; Marzocchi, Giulia; Santoro, Antonio; Cavo, Michele
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma
2015 Cavo, M; Pantani, L; Pezzi, A; Petrucci, M T; Patriarca, F; Di Raimondo, F; Marzocchi, G; Galli, M; Montefusco, V; Zamagni, E; Gamberi, B; Tacchetti, P; Brioli, A; Palumbo, A; Sonneveld, P
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma.
2012 Cavo M; Pantani L; Petrucci MT; Patriarca F; Zamagni E; Donnarumma D; Crippa C; Boccadoro M; Perrone G; Falcone A; Nozzoli C; Zambello R; Masini L; Furlan A; Brioli A; Derudas D; Ballanti S; Dessanti ML; De Stefano V; Carella AM; Marcatti M; Nozza A; Ferrara F; Callea V; Califano C; Pezzi A; Baraldi A; Grasso M; Musto P; Palumbo A.
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma
2016 Pantani, L; Brioli, A; Tacchetti, P; Zannetti, B A; Mancuso, K; Rocchi, Serena; Martello, M; Rizzello, I; Terragna, C; Zamagni, E; Cavo, M
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation.
2008 Tosi P; Terragna C; Testoni N; Zamagni E; Renzulli M; Tacchetti P; Montanari E; Perrone G; Ceccolini M; Brioli A; Pallotti MC; Tura S; Baccarani M; Cavo M.
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5
2012 Terragna, C; Martello, M; Martinelli, G; Durante, S; Pantani, L; Zamagni, E; Tacchetti, P; Brioli, A; Perrone, G; Zannetti, Ba; Borsi, E; Biasco, G; Baccarani, M; Cavo, M.
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma
2013 Kaiser MF;Johnson DC;Wu P;Walker BA;Brioli A;Mirabella F;Wardell CP;Melchor L;Davies FE;Morgan GJ
HIF 1 Alpha: A Suitable Target for Multiple Myeloma
2011 PERRONE G; BORSI E; TERRAGNA C; DURANTE S; MARTELLO M; ALUIGI M; MANCINI M; ZAMAGNI E; TACCHETTI P; BRIOLI A; PANTANI L; ZANNETTI BA; MARTINELLI G; SANTUCCI MA; BACCARANI M; CAVO M
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment
2014 Enrica Borsi;Giulia Perrone;Carolina Terragna;Marina Martello;Elena Zamagni;Paola Tacchetti;Lucia Pantani;Annamaria Brioli;Angela Flores Dico;Beatrice Anna Zannetti;Serena Rocchi;Michele Cavo
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53
2012 Terragna C; Martello M; Pantani L; Patriarca F; Zamagni E; Galli M; Tacchetti P; Petrucci MT; Crippa C; Bringhen S; Brioli A; Offidani M; Perrone G; Zannetti BA; Borsi E; Testoni N; Marzocchi G; Baccarani M; Martinelli G; Cavo M.
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53
2011 TERRAGNA C; MARTELLO M; DURANTE S; PANTANI L; ZAMAGNI E; TACCHETTI P; BRIOLI A; PERRONE G; ZANNETTI BA; BORSI E; BACCARANI M; MARTINELLI G; CAVO M
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.
2014 Walker BA;Wardell CP;Melchor L;Brioli A;Johnson DC;Kaiser MF;Mirabella F;Lopez-Corral L;Humphray S;Murray L;Ross M;Bentley D;Gutiérrez NC;Garcia-Sanz R;San Miguel J;Davies FE;Gonzalez D;Morgan GJ
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease.
2012 Brioli A;Zamagni E;Pasquali S;Tosi P;Tacchetti P;Perrone G;Pantani L;Petrucci A;Zannetti BA;Baccarani M;Cavo M
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma.
2012 Zamagni E; Petrucci A; Tosi P; Tacchetti P; Perrone G; Brioli A; Pantani L; Zannetti B; Terragna C; Baccarani M; Cavo M.
Maintenance therapy in newly diagnosed multiple myeloma: current recommendations.
2014 Brioli, A; Tacchetti, P; Zamagni, E; Cavo, M
Melphalan 200 mg/m2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients
2021 Brioli A.; vom Hofe F.; Rucci P.; Ernst T.; Yomade O.; Hilgendorf I.; Scholl S.; Sayer H.; Mugge L.-O.; Hochhaus A.; von Lilienfeld-Toal M.
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
2011 Zamagni E.; Brioli A.; Tacchetti P.; Zannetti B.; Pantani L.; Cavo M.
Patient with ataxia telangiectasia who developed acute myeloid leukemia.
2011 Brioli A; Parisi S; Iacobucci I; Cavo M; Papayannidis C; Anna Zannetti B; Martinelli G; Baccarani M.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma. | Brioli A;Kaiser MF;Pawlyn C;Wu P;Gregory WM;Owen R;Ross FM;Jackson GH;Cavo M;Davies FE;Morgan GJ | 2013-01-01 | LEUKEMIA & LYMPHOMA | - | 1.01 Articolo in rivista | - |
| Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes | Lucia Pantani;Elena Zamagni;Beatrice Anna Zannetti;Annalisa Pezzi;Paola Tacchetti;Annamaria Briol...i;Katia Mancuso;Giulia Perrone;Serena Rocchi;Patrizia Tosi;Michele Cavo | 2014-01-01 | ANNALS OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment | Zannetti, Beatrice Anna; Zamagni, Elena; Santostefano, Marisa; De Sanctis, Lucia Barbara; Tacchet...ti, Paola; Mancini, Elena; Pantani, Lucia; Brioli, Annamaria; Rizzo, Raffaella; Mancuso, Katia; Rocchi, Serena; Pezzi, Annalisa; Borsi, Enrica; Terragna, Carolina; Marzocchi, Giulia; Santoro, Antonio; Cavo, Michele | 2015-01-01 | AMERICAN JOURNAL OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma | Cavo, M; Pantani, L; Pezzi, A; Petrucci, M T; Patriarca, F; Di Raimondo, F; Marzocchi, G; Galli, ...M; Montefusco, V; Zamagni, E; Gamberi, B; Tacchetti, P; Brioli, A; Palumbo, A; Sonneveld, P | 2015-01-01 | LEUKEMIA | - | 1.01 Articolo in rivista | - |
| Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. | Cavo M; Pantani L; Petrucci MT; Patriarca F; Zamagni E; Donnarumma D; Crippa C; Boccadoro M; Perr...one G; Falcone A; Nozzoli C; Zambello R; Masini L; Furlan A; Brioli A; Derudas D; Ballanti S; Dessanti ML; De Stefano V; Carella AM; Marcatti M; Nozza A; Ferrara F; Callea V; Califano C; Pezzi A; Baraldi A; Grasso M; Musto P; Palumbo A. | 2012-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma | Pantani, L; Brioli, A; Tacchetti, P; Zannetti, B A; Mancuso, K; Rocchi, Serena; Martello, M; Rizz...ello, I; Terragna, C; Zamagni, E; Cavo, M | 2016-01-01 | EXPERT REVIEW OF HEMATOLOGY | - | 1.01 Articolo in rivista | pantaniexpert.pdf |
| Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. | Tosi P; Terragna C; Testoni N; Zamagni E; Renzulli M; Tacchetti P; Montanari E; Perrone G; Ceccol...ini M; Brioli A; Pallotti MC; Tura S; Baccarani M; Cavo M. | 2008-01-01 | EUROPEAN JOURNAL OF HAEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 | Terragna, C; Martello, M; Martinelli, G; Durante, S; Pantani, L; Zamagni, E; Tacchetti, P; Brioli..., A; Perrone, G; Zannetti, Ba; Borsi, E; Biasco, G; Baccarani, M; Cavo, M. | 2012-01-01 | CANCER RESEARCH | - | 4.02 Riassunto (Abstract) | - |
| Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma | Kaiser MF;Johnson DC;Wu P;Walker BA;Brioli A;Mirabella F;Wardell CP;Melchor L;Davies FE;Morgan GJ | 2013-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| HIF 1 Alpha: A Suitable Target for Multiple Myeloma | PERRONE G; BORSI E; TERRAGNA C; DURANTE S; MARTELLO M; ALUIGI M; MANCINI M; ZAMAGNI E; TACCHETTI ...P; BRIOLI A; PANTANI L; ZANNETTI BA; MARTINELLI G; SANTUCCI MA; BACCARANI M; CAVO M | 2011-01-01 | BLOOD | - | 4.02 Riassunto (Abstract) | - |
| HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment | Enrica Borsi;Giulia Perrone;Carolina Terragna;Marina Martello;Elena Zamagni;Paola Tacchetti;Lucia... Pantani;Annamaria Brioli;Angela Flores Dico;Beatrice Anna Zannetti;Serena Rocchi;Michele Cavo | 2014-01-01 | EXPERIMENTAL CELL RESEARCH | - | 1.01 Articolo in rivista | - |
| High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 | Terragna C; Martello M; Pantani L; Patriarca F; Zamagni E; Galli M; Tacchetti P; Petrucci MT; Cri...ppa C; Bringhen S; Brioli A; Offidani M; Perrone G; Zannetti BA; Borsi E; Testoni N; Marzocchi G; Baccarani M; Martinelli G; Cavo M. | 2012-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 | TERRAGNA C; MARTELLO M; DURANTE S; PANTANI L; ZAMAGNI E; TACCHETTI P; BRIOLI A; PERRONE G; ZANNET...TI BA; BORSI E; BACCARANI M; MARTINELLI G; CAVO M | 2011-01-01 | BLOOD | - | 4.02 Riassunto (Abstract) | - |
| Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. | Walker BA;Wardell CP;Melchor L;Brioli A;Johnson DC;Kaiser MF;Mirabella F;Lopez-Corral L;Humphray ...S;Murray L;Ross M;Bentley D;Gutiérrez NC;Garcia-Sanz R;San Miguel J;Davies FE;Gonzalez D;Morgan GJ | 2014-01-01 | LEUKEMIA | - | 1.01 Articolo in rivista | - |
| Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. | Brioli A;Zamagni E;Pasquali S;Tosi P;Tacchetti P;Perrone G;Pantani L;Petrucci A;Zannetti BA;Bacca...rani M;Cavo M | 2012-01-01 | BONE MARROW TRANSPLANTATION | - | 1.01 Articolo in rivista | - |
| Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. | Zamagni E; Petrucci A; Tosi P; Tacchetti P; Perrone G; Brioli A; Pantani L; Zannetti B; Terragna ...C; Baccarani M; Cavo M. | 2012-01-01 | ANNALS OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Maintenance therapy in newly diagnosed multiple myeloma: current recommendations. | Brioli, A; Tacchetti, P; Zamagni, E; Cavo, M | 2014-01-01 | EXPERT REVIEW OF ANTICANCER THERAPY | - | 1.01 Articolo in rivista | - |
| Melphalan 200 mg/m2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients | Brioli A.; vom Hofe F.; Rucci P.; Ernst T.; Yomade O.; Hilgendorf I.; Scholl S.; Sayer H.; Mugge ...L.-O.; Hochhaus A.; von Lilienfeld-Toal M. | 2021-01-01 | BONE MARROW TRANSPLANTATION | - | 1.01 Articolo in rivista | - |
| Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. | Zamagni E.; Brioli A.; Tacchetti P.; Zannetti B.; Pantani L.; Cavo M. | 2011-01-01 | SEMINARS IN THROMBOSIS AND HEMOSTASIS | - | 1.01 Articolo in rivista | - |
| Patient with ataxia telangiectasia who developed acute myeloid leukemia. | Brioli A; Parisi S; Iacobucci I; Cavo M; Papayannidis C; Anna Zannetti B; Martinelli G; Baccarani M. | 2011-01-01 | LEUKEMIA & LYMPHOMA | - | 1.01 Articolo in rivista | - |